Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed neurologic impairment and improved renal damage...
Saved in:
Main Authors: | Ohanian M (Author), Cable CC (Author), Halka KK (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2011-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
by: Halka K, et al.
Published: (2011) -
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
by: Sara Madureira Gomes, et al.
Published: (2021) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
by: Seong Heon Kim, et al.
Published: (2018) -
Rapid Resolution of Atypical Hemolytic Uremic Syndrome by Eculizumab Treatment
by: Min Seung Kim, et al.
Published: (2020) -
Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy
by: Asli Kavaz Tufan, et al.
Published: (2024)